STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #18 by analyst upside · 2026-09-14
SBFM
Sunshine Biopharma, Inc.
Healthcare · Market Cap $4M · P/E 0x
ANALYST PRICE TARGET
+5183.0%
implied upside to consensus target
Current Price $1.06
Consensus Target $56.0
Bull Target $56.0
Bear Target $56.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $1.01
52-Week High $24.3
YTD Return -91.7%
FUNDAMENTALS
Market Cap $4M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-9.16
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $35M
Profit Margin -16.5%
52-WEEK RANGE
52-Week Low $1.01
52-Week High $24.3
Current Price $1.06
Bear Target $56.0
Bull Target $56.0
● Now $1.06 ● Target $56.0
TRADING DATA
Avg Volume 526K
YTD Return -91.7%
Analyst Count 1
Consensus Buy
Upside to Target +5183.0%
Last Updated 2026-09-14

ANALYST SUMMARY

Sunshine Biopharma, Inc. (SBFM) is currently trading at $1.06 with a Wall Street consensus price target of $56.0, implying potential upside of 5183.0% over the next 12 months. 1 analysts currently cover SBFM, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $56.0, while the most cautious has a target of $56.0.

SBFM operates in the Healthcare sector with a market capitalisation of $4M. The stock is down 91.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.01 – $24.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SBFM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Aegis Capital reit
Buy → Buy 2025-10-08 Building track record
Aegis Capital reit
Buy → Buy 2024-12-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →